VP peptides and receptors in diagnosis of breast cancer.

VP 肽和受体在乳腺癌诊断中的应用。

• 批准号: 6966384
• 负责人: WILLIAM G NORTH
• 金额: $ 13.75万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-01 至 2007-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6966384
• 关键词: autoradiography; bioimaging /biomedical imaging; biomarker; breast neoplasms; clinical research; diagnosis design /evaluation; enzyme linked immunosorbent assay; flow cytometry; glycopeptides; hormone inhibitor; hormone receptor; human subject; immunocytochemistry; laboratory mouse; neoplasm /cancer diagnosis; nucleic acid sequence; patient oriented research; polymerase chain reaction; radioimmunoassay; radiotracer; receptor expression; vasopressins; western blottings

DESCRIPTION (provided by applicant):The objective of this project is to improve diagnostic techniques for breast cancer and breast ductal carcinoma in situ (DCIS). The hypothesis being tested is that vasopressin (VP)-related peptides, and VP receptors will provide sensitive and reliable targets for better detection, diagnosis, and eventual treatment of breast cancer and DCIS. Our recent data show VP gene expression is a feature common to all or most breast cancers and DCIS. This expression gives rise not only to a surface marker, GRSA, but also to VP, VP-related glycopeptide (VAG) and ProVP as potential blood markers of disease. Vasopressin receptors also seem to be expressed because VP is an autocrine growth factor for breast cancer. Goals are directed towards: (i) developing effective plasma and tissue ELISA assays for detecting ductal and lobular invasive breast cancer; (ii) assessing the value of such ELISA assays for detecting residual invasive disease and possibly forecasting survival; (iii) ascertaining if the same ELISA assays can be utilized for detecting DCIS in plasma as they most probably can in tissues; and (iv) determining the distribution and abundance in breast cancer and DCIS of an abnormal VP receptor (abnV2R) that is seemingly unique to breast cancer to ascertain if it can be used as a new marker for detection and treatment of breast cancer. These investigations will employ, RIA as well as ELISA assay, RT-PCR, cloning, and DNA sequencing, immunohistochemistry, antibody generation, Western analysis with densitometric quantitation, and flow cytometry. One successful end-point of our studies would be the generation of widely available and sensitive methods for detecting and localizing disease in all, or most, individuals. Another successful end-point would be the finding that these same methods can successfully monitor current treatments, and potentially lead to new and more effective ones.

描述（由申请人提供）：该项目的目的是改善原位乳腺癌和乳腺导管癌的诊断技术（DCIS）。正在检验的假设是加压素（VP）相关的肽和VP受体将提供敏感且可靠的靶标，以更好地检测，诊断和最终治疗乳腺癌和DCIS。我们最近的数据显示，VP基因表达是所有或大多数乳腺癌和DCIS共有的特征。这种表达不仅会引起表面标记GRSA，还会引起VP，与VP相关的糖肽（VAG）和ProVP作为疾病的潜在血液标记。加压素受体似乎也表达了，因为VP是乳腺癌的自分泌生长因子。 目标是针对以下方面的：（i）开发有效的血浆和组织ELISA分析，以检测导管和小叶浸润性乳腺癌； （ii）评估此类ELISA测定的价值，以检测残留的侵入性疾病并可能预测生存； （iii）确定是否可以使用相同的ELISA分析来检测血浆中的DCI，就像它们在组织中一样可能； （iv）确定乳腺癌（ABNV2R）的乳腺癌和DCI的分布和丰度似乎是乳腺癌独有的，以确定是否可以用作检测和治疗乳腺癌的新标记。 这些研究将采用RIA以及ELISA测定，RT-PCR，克隆和DNA测序，免疫组织化学，抗体产生，具有光密度计量定量的西方分析和流式细胞仪。 我们研究的一个成功的终点是生成广泛可获得的敏感方法，用于检测和本地化疾病，或大多数人。另一个成功的终点是发现，这些相同的方法可以成功监控当前治疗方法，并有可能导致新的和更有效的方法。